Keyphrases
5-year Survival
20%
Adoptive Cell Therapy
20%
Adult Cancer
20%
Anti-GD2 Antibody
20%
Antibody-mediated
20%
Artistic Development
20%
Composition Function
20%
Dinutuximab
20%
High-risk Neuroblastoma
40%
Immune Cells
20%
Immune Checkpoint Blockade Antibodies
20%
Immune Checkpoint Molecules
20%
Immune Defense
40%
Immune Landscape
100%
Immunomodulatory
20%
Immunosuppressive Myeloid Cells
20%
Immunotherapeutic Approaches
20%
Immunotherapeutic Intervention
20%
Immunotherapy Strategy
20%
Improved Patient Outcomes
20%
Infiltration
20%
Low Immunogenicity
20%
MHC Class II
20%
Mutational Load
20%
Natural Killer Cells
20%
Neuroblastoma
100%
Neuroblastoma Tumor
20%
Novel Therapeutics
100%
Pediatric Cancer
20%
Pediatric Oncology
100%
Personalization Strategy
20%
Prognostic Value
20%
Small Fraction
20%
Standard of Care
20%
Stromal Cells
20%
Successful Implementation
20%
T Cells
40%
Tumor Immune Evasion
20%
Tumor Immunology
20%
Tumor Infiltration
20%
Tumor Reactivity
20%
Tumor-infiltrating Lymphocytes
60%
Value Function
20%
Medicine and Dentistry
Cell Therapy
12%
Childhood Cancer
100%
Dinutuximab
12%
Ganglioneuroblastoma
100%
Immune Checkpoint Blockade
12%
Immune Evasion
12%
Immunity
100%
Immunocompetent Cell
12%
Immunogenicity
12%
Immunosuppressive Drug
12%
Immunotherapy
50%
Malignant Neoplasm
12%
Mediator
12%
Mutational Load
12%
Myeloid Cell
12%
Natural Killer Cell
12%
Neoplasm
37%
Pediatric Cancer
12%
Secretion (Process)
12%
Stromal Cell
12%
Survival Rate
12%
T Cell
37%
Tumor Escape
12%
Tumor Immunology
12%
Tumor Infiltrating Lymphocyte
37%